Anavex Life Sciences Corp. (AVXL) Financials

AVXL Assets vs Liabilities
DateAssetsLiabilities
Dec. 31, 2025 133.0 million 6.4 million
Sept. 30, 2025 103.8 million 8.9 million
June 30, 2025 102.4 million 11.5 million
March 31, 2025 117.1 million 17.4 million

AVXL Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Dec. 31, 2025 -7.2 million 1.1 million
Sept. 30, 2025 -8.6 million 3.7 million
June 30, 2025 -12.5 million 4.3 million
March 31, 2025 -5.9 million 1.4 million

AVXL Net Income

No data available :(

AVXL Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Dec. 31, 2025 131.7 million - -
Sept. 30, 2025 102.6 million - -
June 30, 2025 101.2 million - -
March 31, 2025 115.8 million - -

AVXL Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Dec. 31, 2025 89.0 million
Sept. 30, 2025 85.9 million
June 30, 2025 85.4 million
March 31, 2025 85.1 million

AVXL Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Dec. 31, 2025 - 4.7 million 2.1 million -
Sept. 30, 2025 - 7.3 million 3.6 million -
June 30, 2025 - 10.0 million 4.5 million -
March 31, 2025 - 9.9 million 2.6 million -

AVXL Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Dec. 31, 2025 - -
Sept. 30, 2025 - -
June 30, 2025 - -
March 31, 2025 - -

AVXL

Price: $2.50

52 week price:
2.41
13.99

Earnings Per Share: -0.46 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 1.1 million

Ebitda: -4.1 million

Market Capitalization: 231.7 million

Links: